Stakeholder Engagement in Planning the Design of a National Needs Assessment for Cardiovascular Disease Prevention and Management in Nepal

Shrestha Archana*†, Biraj Man Karmacharya*†, Maharjan Rashmi*, Vaidya Abhinav†, Dhimal Meghnath‖, Oli Natalia§, Shrestha Rajeev*, Pyakurel Prajwal‖, Fitzpatrick Annette**†††, Citrin David†‡‡, Spiegelman Donna†‡‡, Koju Rajendra†††

Kavrepalanchwok, Kathmandu, and Dharan, Nepal; Boston, MA, USA; Seattle, WA, USA; New Haven, CT, USA; and Guangzhou, China

ABSTRACT

Background: There is growing support for stakeholder engagement in health research, but the actual impact of such engagement has not been well established.

Objectives: This paper describes the stakeholder engagement process and evaluation during the planning of the national needs assessment for cardiovascular disease in Nepal.

Methods: We used personal and professional networks to identify relevant stakeholders within the 7Ps framework (Patients and the Public, Providers, Purchasers, Payers, Public Policy Makers and Policy Advocates, Product Makers and the Principal Investigators) to develop a plan for assessing cardiovascular health needs in Nepal. We consulted 40 stakeholders through 2 meetings in small groups and a workshop in a large group to develop the study methods, conceptual framework, and stakeholder engagement process. We interviewed 33 stakeholders to receive feedback on the stakeholder engagement process.

Results: We engaged 80% of the targeted stakeholders through small group discussions and a workshop. Three of 5 recommendations from the small group discussion were aimed at improving the stakeholder engagement process and 2 were aimed to improve the research methods. Eleven of 27 recommendations from the workshop aimed to improve the research methods, 4 aimed to improve stakeholder engagement, and 2 helped to expand the scope of dissemination. Ten were irrelevant or could not be incorporated due to resource limitation. Most stakeholders noted that the workshop provided an open platform for a multisectoral group to colearn from one another and share ideas. Others highlighted that the discussion generated insights to enhance research by incorporating expertise and ideas from different perspectives. The major challenges discussed were about committing the time for engagement.

Conclusions: The stakeholder engagement process positively affected the design of our research. This study provides important insights for future researchers that aim to engage stakeholders in national-level assessment programs in the health care system in the context of Nepal.
engagement process and report its impact on individual projects [3], there is limited reporting of the process and even less of evaluation of the engagement process. Here, we describe the stakeholder engagement and evaluation while planning the national needs assessment for cardiovascular disease (CVD) prevention and management in Nepal.

**METHODS**

**Setting**

Project: Translational Research Capacity Building Initiative to address CVD in Nepal. The project aims to build national capacity to lead translational research in CVD by creating and training a multisectoral, multidisciplinary team, building partnership with U.S. and regional institutions; systematically assessing national needs; and developing an actionable translational research plan. CVD are the leading causes of premature deaths in the world with >80% of all CVD-related deaths occurring in low- and middle-income countries [9]. In Nepal, CVD risk factors have increased alarmingly over the past decades, increasing by 43% and 41% in deaths due to ischemic heart disease and stroke, respectively, between 2007 and 2017 [9,10]. Proven cost-effective strategies are available for reducing cardiovascular diseases in low-income settings including both population-wide and individual risk approaches. However, scaling up these interventions is challenging especially in a low-income country such as Nepal. Not only is individual behavior modification complicated by sociocultural and environmental factors; in addition the health care delivery system is not set up to address prevention and treatment, nor have adequate resources been dedicated toward these efforts to address prevention and treatment. Specifically, enormous gaps exist in the following: 1) epidemiological understanding of CVD and their risk factors (modifiable and non-modifiable); 2) national level policies and strategies to address CVD; 3) health care systems infrastructure to provide education and treatment; 4) community- and patient-level support; 5) development and application of national registries for CVD; and 6) human resources to lead and implement the agendas to address the growing burden of CVD in Nepal.

A multifaceted, multisectional synergistic effort is required for the sustainable uptake of evidence-based interventions into routine clinical and community-based settings. Given the complexities, it is important to train and build the capacity of the Nepali researchers to identify local needs for CVD and develop feasible context-specific implementation strategies to deliver evidence-based interventions. To lay this groundwork, Dhulikhel Hospital—Kathmandu University Hospital has built a collaborative team of Nepalese and international experts to build capacity, assess national needs, and develop an actionable translational research plan to address the growing burden of CVD in Nepal. We have also enrolled 16 research fellows from diverse professional backgrounds.

The overall aim of the national needs assessment is to investigate the CVD epidemiology and national capacity to prevent and manage CVD in Nepal. The specific aims are 1) to assess national-level infrastructure and capacity for CVD prevention and management interventions in Nepal on leadership and governance, health service delivery, health financing, human resources, pharmaceuticals and medical products, and health information system and 2) to assess the CVD burden and severity in Nepal using available secondary data. The main outcome of the assessment is to report key findings for each health system function, highlighting important strengths, critical cross-cutting health system weaknesses that limit performance, and recommendations for priority interventions. In addition, the findings, priorities, and recommendations have to be corroborated and validated by key stakeholders at the national level. The results of the assessment will be utilized to prioritize national CVD health needs, design relevant interventions, and develop a translational research plan.

**Conceptual framework**

We used Ray and Miller’s framework [3] for planning, evaluating, and reporting stakeholder engagement. The framework is illustrated in Table 1. As our study is in an early phase, we are only able to report immediate outcomes in this paper.

**Context**. In the context of an overall research agenda of assessing national needs for the prevention and management of CVD, we planned to engage a wide range of stakeholders from different sectors. There was a high level of commitment from researchers to engage relevant stakeholders in the process. The desired inputs were the

| TABLE 1. Conceptual model for understanding the impact of stakeholder engagement |
|-----------------------------------------------|
| **Context** | **Processes** | **Immediate Outcomes** | **Intermediate Outcomes** | **Long term Outcomes** |
| Resources | Stakeholder recruitment | Research questions | Research value | Health outcomes |
| Attitudes | Composition | Methods | Efficiency | Patient decision making |
| Expectations | Decision making | Analysis | Uptake | Health policy |
| Inputs and outputs sought | Frequency of engagement | Results | Interpretation | Ethics |
| Dissemination | |

Based on Ray and Miller’s framework [3].
values, knowledge, and experience of a range of stakeholders. The desired outputs were to incorporate the inputs to improve research objectives, scope, and methods and to guide subsequent research efforts. External funding and dedicated time were available for the stakeholder engagement and evaluation.

The purpose of the stakeholder engagement was to incorporate a broad range of experiences in the planning and execution of the needs assessment to enhance interpretability and relevance of findings suited for local context. The stakeholders were consulted specifically for developing the study methods, conceptual framework, and stakeholder engagement process. In the long run, stakeholders are planned to be engaged at different levels: 1) inform—to provide stakeholders with balanced and objective information to help them understand the needs assessment process, results, and recommendations; 2) consult—to obtain inputs from stakeholders on the process, results, and recommendations; 3) involve—to work with stakeholders throughout the process to ensure their feedback is incorporated; 4) collaborate—to partner with stakeholders for conducting the needs assessment by defining objectives, collecting data, analyzing data, and interpreting the results; and 5) empower—to engage in the needs assessment process with shared power in decision-making process for conducting the assessment.

Processes

Stakeholder recruitment and composition. We defined a stakeholder as an individual or group affected by CVD or in a position to directly influence CVD prevention and management at a national level in Nepal. We adopted the 7Ps framework (Patients and the Public, Providers, Purchasers, Payers, Public Policy Makers and Policy Advocates, Product Makers and the Principal Investigators) [11] that identifies key groups to consider for engagement. The first group, patients and the public, represents the current and potential consumers of patient-centered health care and population-focused public health services. The second were providers, including individuals and organizations that provide care to patients and populations. Purchasers, the individuals and entities responsible for underwriting the costs of health care, such as employers, made up the third group. The fourth group consisted of payers who were responsible for reimbursement of medical care, such as insurers. The fifth is composed of public policy makers and policy advocates working in the nongovernmental sector. Product makers, representing drug and device manufacturers, composed the sixth group, and principal investigators, or other researchers, made up the seventh. We used personal and professional networks to identify relevant stakeholders within the 7Ps framework. Furthermore, we updated the list after receiving feedback in our first stakeholders’ meeting. We received ethical approval to include human subjects (stakeholders) from the Institutional Review Committee of Kathmandu University School of Medical Sciences, an independent body approved by Nepal Health Research Council.

Frequency and duration of engagement. For planning of the needs assessment, we interacted with the stakeholders on 3 separate occasions: during 2 meetings with a smaller group of 15 people and 1 workshop with a group of 37 stakeholders.

Small group meetings: We formed a task force to guide and lead the needs assessment process that was cochaired by the principal investigator of the Translational Research Capacity Building Initiative to address CVD in Nepal and the executive chairperson of the Nepal Health Research Council (NHRC), an apex body for health research in Nepal. There are coinvestigators, a heart patient, a representative from Cardiac Society of Nepal, representatives from the Ministry of Health and Population, and members from NHRC on the task force. The task force aims to meet 4 times a year to plan and oversee the needs assessment process. We conducted 2 1-h task force meetings to discuss the needs assessment proposal and receive feedback.

Stakeholder workshop: We conducted a 3-h workshop with 40 stakeholders to present the needs assessment plan and receive feedback. The stakeholders introduced themselves to the large group. Then, we provided a brief orientation to the preliminary research topic, conceptual framework, and methods using a PowerPoint (Microsoft, Redmond, WA) presentation to promote full participation. We stimulated colearning by ensuring that each stakeholder had at least a 5-min dedicated time to speak and encouraged them to ask questions and share their experiences and expertise. We addressed concerns or queries raised by the stakeholders. Two research team members were dedicated to recording all comments and recommendations in a log.

Setting expectations and decision making. At our first stakeholder workshop, we revisited expectations and invited further dialogue in roles and responsibilities. For the task force, we also prepared a terms of reference document that specified the roles of stakeholders, power dynamics, and decision-making process.

Immediate outcomes. The principal investigator and coinvestigators further discussed the feedback and revised the research questions, scope, and methods.

Evaluation of stakeholder engagement. We approached 37 stakeholders for an interview to receive feedback on the stakeholder engagement process. This explored perspectives of the stakeholders regarding the engagement process and how it could be improved in future.

We asked their feedback in relation to the following themes: 1) expectations from the engagement process; 2) representation of stakeholders; 3) degree of involvement;
4) engagement channels and methods; 5) future expectations; and 6) benefits and barriers to engagement. The interviews were semistructured and were administered in person or by telephone by a coinvestigator and a research officer. The responses were coded manually and analyzed thematically.

RESULTS

Stakeholders and purpose of engagement

Based on the 7Ps framework, we present stakeholders and the purpose of engagement in Table 1. A total of 50 stakeholders were identified, 40 of which accepted our invitation and were engaged. Of the 10 who were not engaged, 6 had other conflicting time commitments and 4 cited personal reasons for not attending any interaction programs. We achieved a balanced composition of our stakeholder group, with 5 representatives from patients and public; 5 representatives from providers, 3 purchasers, 4 payers, 5 policy makers, 4 product makers, and 14 research team members, including investigators and research assistants. Stakeholder mapping has been illustrated in Table 2.

| Types | Stakeholders | Purpose of Engagement |
|-------|--------------|-----------------------|
| Patients and the public: current and potential | Heart patient | Inform: provide balanced and objective information to help them understand the needs assessment process, results, and recommendations |
| CVD patients their caregivers, families, and consumer advocacy organizations | Family member of heart patient | |
| Providers: individuals (e.g., nurses, physicians, health counselors, pharmacists, and other providers of care and support services) and organizations (e.g., hospitals, clinics, community health centers, community-based organizations, pharmacies) that provide care to patients and populations | Nepal Medical Association | Involve: to work with stakeholders throughout the process to ensure their feedback is incorporated |
| | Cardiac Society of Nepal | |
| | Nepal Nursing Association—representative | |
| | Nepal Health Professional Council—representative | |
| | Female Community Health Volunteer—representative | |
| | Patient—out-of-pocket payers | Collaborate: partner in the needs assessment conduction: defining objectives, data collection, data analysis, and interpretation |
| | Family member—out-of-pocket payers | |
| | Noncommunicable disease section, Department of Health Services Epidemiology and Disease Control Division Health Management Information System National Health Training Center | |
| | Ministry of Health and Population—Health Insurance Board Ministry of Health and Population—Nursing and Social Security Division NGO for CVD—representative | Consult: obtain inputs on the process, results, and recommendations |
| Purchasers: employers, the self-insured, government, and other entities responsible for underwriting the costs of health care | Ministry of Health and Population | Empower: engage in the needs assessment process with shared power in decision-making process |
| | National Planning Commission Nepal Health Research Council | |
| Policy makers: national- and province-level health planners and other policy-making entities | Ministry of Health and Population | |
| | National Planning Commission Nepal Health Research Council | |
| Product makers: drug and device manufacturers | Association of Pharmaceutical Producers of Nepal, Local Pharmacies Department of Drug Administration, Nepal Chemist and Druggist Association Private for profit provider—representative (Norvic) Teaching hospitals (Nepal Medical College) | Consult: obtain inputs on the process, results, and recommendations |
| Principal investigators: other researchers and their funders | Researchers | Empower: to engage in the needs assessment process with shared power in the decision-making process |

CVD, cardiovascular disease; NGO, nongovernmental organization.
Immediate outcomes

Discussion during task force meetings and influence on the needs assessment plan. The recommendations and their effects on the need assessment plan are summarized in Table 3. All 5 recommendations made during the task force meetings were incorporated into the needs assessment plan. Three of the recommendations focused on improving the stakeholder engagement process, whereas 2 recommendations were aimed at improving or modifying methods to align with stakeholder priorities.

Discussion during stakeholder workshop and influence on the needs assessment plan. During the discussion session in the workshop, we received a total of 28 recommendations. Of these, 16 recommendations were incorporated. Eleven helped to improve research methods, 4 to improve stakeholder engagement, and 2 to expand the scope of dissemination. The recommendations and affects that were incorporated are summarized in Table 4. Seven recommendations were beyond the scope of this study, and 5 were relevant but could not be incorporated due to resource limitations. The recommendations that were not incorporated with the reasons why are summarized in Table 5.

Intermediate and long-term outcomes

As our research and engagement process is in the early phase, we are not able to assess and report intermediate and long-term outcomes.

Evaluation of stakeholder engagement

Eighy-nine percent of the stakeholders who attended the workshop responded to our interview calls (n = 33).

Expectations from the engagement process. Only about one-half of the participants mentioned that they were aware of the purpose of the meeting and their specific roles prior to attending the event. Several participants underscored the need of pre-meeting information sharing and preparation before the workshop.

One participant said, “I came because my friend couldn’t come and she asked me to participate on her behalf. I didn’t have any idea of what the program was about.” “Role and expectation from all the stakeholders must be clarified earlier. Since there are different levels of stakeholders, clarity is required beforehand” (a participant from principal investigator group of 7Ps framework).

Representation of stakeholders. Almost all of the participants (32 of 33) said that relevant people were invited. Some suggested to include the following stakeholders in subsequent meetings: 1) caretakers of heart patients; 2) representatives of Female Community Health Volunteers from other areas (in the first meeting, Female Community Health Volunteers from only 1 district were invited); 3) government representatives from local levels; 4) representatives from the Ministry of Finance; 5) consumers’ groups; 6) health providers working in rural areas; 7) gender experts; 8) representatives from other ministries, and 9) health economists.

| Recommendations | Responses | Effect on |
|-----------------|-----------|-----------|
| Access the needs of the districts implementing PEN separately | Plan to purposively select one-half of the sample districts with PEN program | Design |
| Assess pharmaceuticals and medical supplies for CVD prevention and management | Added pharmaceuticals and medical supplies in the conceptual framework | Design |
| Increase role of government representative in implementing and interpreting the results to keep the assessment process aligned with the government’s priority and to facilitate the uptake of the assessment results | Invited 2 government representatives in the task force. | Stakeholder engagement |
| Clarify the role and power of Nepal of Health Research Council in the needs assessment plan | Jointly developed a detail terms of reference clarifying expectations, role, and power of Nepal Health Research Council | Stakeholder engagement |
| Involve the CVD translational research fellows in the need assessment process to increase the scope of the study | Conducted a workshop with CVD translational research fellows to explore their involvement | Stakeholder engagement |

CVD, cardiovascular disease; PEN, Package of Essential Noncommunicable Diseases.
Participants from the Ministry of Health and Population suggested that more government representation was required not just in the assessment process but also as researchers or research fellows. One government representative said, “If we aim for changes at the national level, there has to be active participation of government representatives in the research.”

**Degree of involvement.** More than one-half of the participants (n = 16) said that they actively participated in the stakeholder workshop and felt that their inputs were accepted and addressed in the discussion. Research team members who were involved in developing the preliminary needs assessment plan chose not to speak much in order to provide more time and space for other stakeholders. All participants unanimously agreed that they were included well in the discussions.

**Engagement channels and methods.** None of the participants said that the further engagement plan of the stakeholders (4 workshops with similar intensity and activity in 2 years) would be too much. In fact, almost one-third of them said that might not be enough time (n = 11). Participants were also willing to share their views and opinions in the future through phone calls (n = 17), e-mails and letters (n = 21), and in-person meetings (n = 14). More than one-half of the participants believed their task was to inform or consult the project team (n = 15) and about one-third thought that they had to be involved in the process as well (n = 11).

### TABLE 4. Recommendations during stakeholder workshop and effect on the needs assessment plan

| Recommendations | Response | Effect on |
|----------------|----------|-----------|
| Assess the needs of CVD prevention and management at provincial level | Planned to stratify the data collection and analysis by the province | Design |
| Explore the prescription and availability of generic drugs as an option to lower drug cost | Added the metrics to assess the availability of generic drugs and added questions in the key informant interview guide to explore the use of generic drugs | Design |
| Explore the challenges of implementing PEN package in terms of access to medicine and referral mechanism | Added a theme to explore barriers of PEN implementation | Design |
| Assess the availability of lifestyle modification programs at different levels of the health care system | Added a theme to assess the availability and functioning of lifestyle modification programs | Design |
| Explore the referral mechanism to treat CVD complication | Added a theme to assess the availability and functioning of lifestyle modification programs | Design |
| Explore task shifting of CVD care and management from physicians to other health professionals | Added a theme to explore the perception, facilitators, and barriers to task shifting of CVD and hypertension patient care to paramedics | Design |
| Assess the current role of nonlicensed providers (quacks) in treating hypertension and diabetes | Added quacks as key informants to explore their role in hypertension and diabetes management in the community | Design |
| Assess urban rural disparity in access to health care | Added urban rural disparity assessment in data analysis plan | Design |
| Assess knowledge regarding the availability and cost of health services among CVD patients | Added a theme to explore health literacy among CVD patients | Design |
| Obtain health financing data from Social Health Security Section of DoHS | Added the Social Health Security Section as a data source on health financing | Design |
| Communicate the assessment findings with policy makers in short reports | Added preparing and presenting research and policy briefs in the dissemination plan | Dissemination |
| Disseminate the assessment findings to public using multiple portals | Added plan to disseminate the findings in the general meetings of social clubs and annual review meetings of the DoHS | Dissemination |
| Facilitate the use of assessment results by CVD translational fellows and other researchers | Planned to make the data and results available to the translational research fellows for further analysis | Stakeholder engagement |
| Add the DoHS and DoHPP in the research team | Invited the representatives of DoHS and DoHPP in the task force | Stakeholder engagement |
| Involve NHTC in the assessment process | Added NHTC on stakeholder roster and planned to invite them to subsequent meetings | Stakeholder engagement |
| Involve nutritionists and dieticians in the assessment process | Added a nutritionist on stakeholder and planned to invite them to subsequent meetings | Stakeholder engagement |

DoHS, Department of Health Services; DoHPP, Department of Health Policy and Planning; NHTC, National Health Training Center; other abbreviations as in Tables 2 and 3.
Many participants highlighted that the interactive sessions with smaller groups can be more informative. As 1 participant said, “Rather than long discussions on different topics, it would have been better to have multiple short presentations, followed by interactions among smaller groups on different topics.”

There was also a concern regarding the heterogeneity of the group, potentially affecting the understandability of the discussions. One participant mentioned, “Patients and caretakers might not be able to grasp the technical details of the presentations and the discussions.”

**Benefits of stakeholder engagement.** Almost all participants said that the workshop provided an open platform for a multisectoral group to colearn from each other and share ideas. It helped to enhance the research design process by incorporating expertise and ideas from different perspectives early on. Other benefits that were noted were the following: 1) commitments from policy level; 2) awareness of all relevant professionals on what to expect from CVD prevention and management needs assessment; 3) identification of the gaps in the assessment plan; 4) team building; and 5) enhanced ownership. Some participants stated that participation at the planning phase can lead to improved implementation of the assessment process, validation of findings, and ownership of the results.

**Challenges of stakeholder engagement.** About one-third of the participants (n = 10) mentioned that it is challenging to commit time for conducting research. Some mentioned that engaging the same government officials throughout the research process will be difficult because of their frequent transfer. Other major challenges that were noted include the following: 1) difficulties around comprehending and incorporating feedback from a diverse group of people; 2) varying levels of pre-existing knowledge and expertise, which makes it challenging to discuss with all of them together in a single forum; and 3) challenges around professional or personal aspirations.

---

**TABLE 5. Recommendations that were not included in the needs assessment plan**

| Recommendations                                                                 | Reason                        |
|--------------------------------------------------------------------------------|-------------------------------|
| Collect primary data to map the situation of CVD in Nepal                      | Resource limitation           |
| Develop and evaluate treatment guidelines for managing hypertension, myocardial infarction, stroke, and other CVD | Resource limitation           |
| Quantify the health literacy, particularly CVD knowledge in the general population | Resource limitation           |
| Establish a nationwide surveillance of myocardial infarction, stroke, and rheumatic heart disease | Resource limitation           |
| Estimate death and disability rates due to CVD using a population-based survey | Resource limitation           |
| Conduct clinical trials to test effectiveness of various interventions on CVD management | Beyond the scope of the study |
| Assess the quality of medicines available in the market                        | Beyond the scope of the study |
| Quantify the antibacterial resistance at the population level                  | Beyond the scope of the study |
| Assess influence of fast food and high sugar beverage consumption on CVD rates | Beyond the scope of the study |
| Assess school environments to develop CVD prevention strategy at an early age  | Beyond the scope of the study |
| Register and monitor tonsillitis among children to prevent rheumatic heart disease | Beyond the scope of the study |
| Prepare a lifestyle modification protocol to prevent and manage CVDs          | Beyond the scope of the study |

CVD, cardiovascular disease.

**TABLE 6. Challenges and barriers and proposed ways to overcome them for stakeholder engagement**

| Challenges for Stakeholder Engagement                                           | Structural Barriers                           |
|-------------------------------------------------------------------------------|-----------------------------------------------|
| Difficult to commit time                                                     | Political uncertainty                         |
| Uncertainty of the tenure of the government officials                         | Conflicting priorities of stakeholders        |
| Varying levels of pre-existing knowledge and expertise among stakeholders     |                                               |
| Varying professional and personal aspirations among stakeholders that may not be relevant to the research process |                                               |
| Difficult to comprehend and incorporate feedback from a diverse group of people |                                               |

| Overcoming Challenges for Stakeholder Engagement                            | Overcoming Structural Barriers With Facilitators |
|----------------------------------------------------------------------------|-----------------------------------------------|
| Providing prior clear information to stakeholder and obtain inputs on specific issues | Present the burden and severity of CVD to stakeholders |
| Engage stakeholders continuously throughout the process                      | Continuously communicate with the stakeholders, especially from the government using different means such as workshops, in-person consultations, e-mails, telephone |
| When possible, have a written term of reference and/or agreement             |                                               |
| Clarify roles and responsibilities of the stakeholders                      |                                               |
| Plan for small group interactions where people can dedicate more time to discuss |                                               |

CVD, cardiovascular disease.
among stakeholders that may not be relevant to the research process. We have summarized the major challenges, barriers, and the proposed ways to address them for stakeholder engagement in Table 6.

DISCUSSION

We describe the experience of stakeholder engagement in planning the national level needs assessment for CVD prevention and management in Nepal and evaluation of the engagement process. We specifically investigated how the stakeholder engagement affected our needs assessment plan and their feedback to improve the stakeholder engagement process in future. We were able to engage 80% of the targeted stakeholders identified using the 7Ps framework [11], representing different groups of service users, providers and policy makers, patients and public, providers, purchasers, payers, policy makers, product makers, and principal investigators. The recommendations from the stakeholder engagement process led to modifications in our needs assessment plans aimed at improving design, dissemination plan, and further stakeholder engagement.

A core element of stakeholder engagement is the identification and prioritization of stakeholders [9]. The 7Ps framework [11] helped us identify a comprehensive list of relevant stakeholders that are directly affected by CVD or can influence CVD prevention and management. The discussion during the workshop and the post-workshop survey reaffirmed that the list was comprehensive; only a few additions were suggested. We updated our list, and the additional members will be invited in subsequent meetings.

Our stakeholder engagement did not just aim to gather inputs, but it also worked to foster a long-term relationship throughout the subsequent steps of the needs assessment implementation and uptake of results. Stakeholder engagement is a complex and dynamic process. It is a fundamental step not just prior to any major policy formulation but also necessary throughout the process of program implementation, monitoring, and evaluation [11,12]. We, therefore, sought to involve different stakeholders at different levels. We forged a formal partnership between Kathmandu University School of Medical Sciences (the host institution of the principal investigator) and the NHRC through a Memorandum of Understanding and the creation of the needs assessment task force cochaired by the principal investigator and the executive director of NHRC. This was aimed at creating an equitable relationship between stakeholders and decision makers.

Of 33 total recommendations, 21 contributed to improving the research plan. Other investigators have also reported to have improved research methods and processes through stakeholder engagement [7]. Furthermore, engaging a diverse group led to covering a wide range of recommendations. For example, government representatives highlighted the need to be mindful of the ongoing changes in the national health system due to the ongoing transition to the federal system and around aligning the assessment with continuously shifting government priorities. Representatives from academic institutions underscored the need of academia-policy linkages and suggested sharing research results via policy briefs. The patients emphasized the need for a referral system, improved health information system, and broader access to health services. The pharmaceutical organizations emphasized the need to explore cost analyses of generic drugs and involving quacks (nonlicensed providers) as respondents in assessing the health utilization pattern at the community level.

Almost one-half of the stakeholders were not clear about the purpose of the meeting before attending. Despite this, stakeholders described satisfaction and some expressed willingness to participate more frequently than planned. Almost all participants said that the workshop provided an open platform for the multisectoral group to learn from one another and share ideas. It helped to enhance research by incorporating expertise and ideas from a different perspective. Stakeholder engagement has been reported to empower stakeholders in other settings [7].

Many participants mentioned that it is challenging to commit time for contributing to the research. Some mentioned that continued engagement of the government officials would be difficult because they are transferred from one place to another within a short time. The challenge of time management has been reported previously. Snape et al. [13] found significant disagreement between stakeholders on the purpose of engagement in research as well as its justification for ethical and patient empowerment grounds.

We have engaged the stakeholders in an early phase of our research. It has been argued that stakeholder partner engagement in early stages of the research process aids in the translation and interpretation of the findings, which ultimately increases the “actionability” of research results [4–11]. By incorporating patients and other stakeholders as partners throughout the research process, they can effectively serve as early ambassadors of research efforts and subsequent findings, which may help to extend to audiences beyond peer-reviewed journals and may facilitate increased uptake of results into the community and health care setting, thereby accelerating its adoption into practice [14–16].

Our study has 3 major strengths. First, it provides a unique perspective on the national health system assessment (for CVD prevention and management) through stakeholder engagement in a low-income setting. Second, we report the process, immediate output, and evaluation of an early stage stakeholder engagement. Third, we have used evidence-informed frameworks to identify the relevant stakeholders and to plan, implement, and evaluate the engagement process, which has facilitated transparency and quality of stakeholder engagement in planning a research. This can facilitate understanding of the best practices of stakeholder engagement.
This study has some limitations. We were not able to assess the intermediate-level and long-term influence of the research because we are at an early stage of our research. In the future, we plan to evaluate the intermediate- and long-term outcomes using a standard framework. Another limitation is that we used a semistructured questionnaire to evaluate the engagement process. It corroborates with other studies that have described the lack of robust tools available for evaluation of engaged research [7,8].

CONCLUSIONS
Our study reafirms that stakeholder engagement can positively affect the design of a research process. We received invaluable recommendations from stakeholders, which were incorporated to improve the needs assessment plan. We recommend that a structured evaluation of stakeholder engagement be developed and implemented in the future to accurately examine the intended success of stakeholder engagement. Although this study was small, it provides important insights for future researchers that aim to engage stakeholders in national-level assessment programs in health.

ACKNOWLEDGMENTS
The authors acknowledge the contribution of all stakeholders to provide feedback.

REFERENCES
1. Woolf SH. The meaning of translational research and why it matters. JAMA 2008;299:211–3.
2. Kok MO, Gyapong JO, Wolffers I, Ofori-Adjei D, Ruitenberg J. Which health research gets used and why? An empirical analysis of 30 cases. Health Res Policy Syst 2016;14:36.
3. Ray KN, Miller E. Strengthening stakeholder-engaged research and research on stakeholder engagement. J Comp Eff Res 2017;6:375–89.
4. Shippee NO, Domecq Garces JP, Prutsky Lopez GJ, et al. Patient and service user engagement in research: a systematic review and synthesized framework. Health Expect 2015;18:1151–66.
5. Mullins CD, Abdulhalim AM, Lavallee DC. Continuous patient engagement in comparative effectiveness research. JAMA 2012;307:1587–8.
6. Lowes L, Holtatt I. Involving Service Users in Health and Social Care Research. London, United Kingdom: Routledge, 2013.
7. Esmail L, Moore E, Rein A. Evaluating patient and stakeholder engagement in research: moving from theory to practice. J Comp Eff Res 2015;4:133–45.
8. Concannon TW, Fuster M, Saunders T, et al. A systematic review of stakeholder engagement in comparative effectiveness and patient-centered outcomes research. J Gen Intern Med 2014;29:1692–701.
9. Ralston J, Reddy KS, Fuster V, Narula J. Cardiovascular diseases on the global agenda: the United Nations high level meeting, sustainable development goals, and the way forward. Glob Heart 2016;11:375–9.
10. Institute for Health Metrics and Evaluation. Nepal. 2015. Available at: http://www.healthdata.org/nepal. Accessed January 24, 2019.
11. Concannon TW, Meissner P, Grunbaum JA, et al. A new taxonomy for stakeholder engagement in patient-centered outcomes research. J Gen Intern Med 2012;27:985–91.
12. Andriof J, Waddock S, Husted B, Rahman S. Unfolding Stakeholder Thinking: Theory, Responsibility and Engagement. Routledge; 2017.
13. Snape D, Kirkham J, Preston J, et al. Exploring areas of consensus and conflict around values underpinning public involvement in health and social care research: a modified Delphi study. BMJ Open 2014;4:e004217.
14. Saunders C, Crossing S, Girgis A, Butow P, Penman A. Operationalising a model framework for consumer and community participation in health and medical research. Aust New Zealand Health Policy 2007:4:13.
15. McKenzie A, Hanley B. Consumer and Community Participation in Health and Medical Research: A Practical Guide for Health and Medical Research Organisations. Perth, Australia: The University of Western Australia, 2012.
16. Abma TA, Nierse CJ, Widdershoven GAM. Patients as partners in responsive research: methodological notions for collaborations in mixed research teams. Qual Health Res 2009;19:401–15.